Clopidogrel mechanism of action

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Clopidogrel Activation and Metabolism: Cytochrome P450 Pathway

Clopidogrel is a prodrug, meaning it must be metabolized in the body to become active. This activation occurs mainly in the liver through the cytochrome P450 enzyme system, particularly the CYP1A and CYP2B6 subfamilies. The active metabolite is generated by these enzymes and is responsible for clopidogrel’s antiplatelet effects. Without this metabolic activation, clopidogrel remains inactive and does not inhibit platelet aggregation Savi1998Savi1994Richter2004.

Clopidogrel’s Target: P2Y12 ADP Receptor on Platelets

The main mechanism of action of clopidogrel is the irreversible inhibition of the P2Y12 receptor, a G protein-coupled receptor found on the surface of platelets. This receptor is crucial for ADP-induced platelet activation and aggregation. Clopidogrel’s active metabolite binds specifically and irreversibly to the P2Y12 receptor, blocking ADP from activating the receptor and thus preventing platelet aggregation. This effect is specific to P2Y12 and does not affect other ADP receptors like P2Y1 or P2X1 Savi2006Savi2005Kuszynski2022+2 MORE.

Molecular Effects on Platelet Function

By inhibiting the P2Y12 receptor, clopidogrel disrupts several downstream signaling pathways in platelets. These include the inhibition of adenylyl cyclase downregulation, reduced protein tyrosine phosphorylation, and prevention of glycoprotein IIb/IIIa complex activation, which is necessary for fibrinogen binding and platelet aggregation. Clopidogrel also impairs the ADP-induced decrease in cAMP-dependent phosphorylation of vasodilator-stimulated phosphoprotein (VASP), a marker of platelet inhibition Savi1998Geiger1999.

Irreversible Binding and Duration of Effect

Clopidogrel’s active metabolite forms a covalent bond with the P2Y12 receptor, leading to irreversible inhibition. This means that the affected platelets remain inhibited for their entire lifespan, even after the drug is cleared from the bloodstream. New platelets must be produced to restore normal platelet function Savi2005Wallentin2009.

Additional and Pleiotropic Effects

While clopidogrel’s primary action is on platelets, the P2Y12 receptor is also found in other tissues, such as leukocytes and vascular cells. This may explain some non-hemostatic effects of clopidogrel, including potential roles in reducing inflammation and fibrosis, as seen in studies on chronic kidney disease and vascular modulation Chen2022Kuszynski2022Yang1997.

Conclusion

Clopidogrel works by being metabolized in the liver to an active form that irreversibly inhibits the P2Y12 ADP receptor on platelets. This blocks ADP-induced platelet activation and aggregation, providing its antithrombotic effect. The specificity and irreversibility of this action make clopidogrel a key drug for preventing blood clots in various cardiovascular conditions Savi1998Savi2006Savi2005+5 MORE.

Sources and full results

Most relevant research papers on this topic

Clopidogrel: a review of its mechanism of action.

Clopidogrel is a potent antithrombotic drug that inhibits ADP binding to platelet receptors, making it a valuable tool for studying ADP's effect on platelets.

Highly Cited

1998·

132citations

·P. Savi et al.

Platelets·

DOI

The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.

Clopidogrel and its active metabolite Act-Met disrupt P2Y12 receptor oligomers and partition them out of lipid rafts, affecting platelet activation.

In Vitro StudyHighly Cited

2006·

329citations

·P. Savi et al.

Proceedings of the National Academy of Sciences of the United States of America·

DOI

Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.

Clopidogrel and ticlopidine effectively prevent atherothrombosis by targeting platelet P2Y12 receptors, with clopidogrel showing greater benefits in patients at risk of ischemic events and unstable angina.

Highly Cited

2005·

338citations

·P. Savi et al.

Seminars in thrombosis and hemostasis·

DOI

The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1A

Clopidogrel's antiaggregating activity is mainly due to its metabolic activation by the hepatic Cytochrome P450-1A subfamily pathway.

Non-RCTAnimal StudyHighly Cited

1994·

293citations

·P. Savi et al.

Thrombosis and Haemostasis·

DOI

P2Y12 inhibitor, Clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition.

Clopidogrel effectively inhibits renal fibrosis in chronic kidney disease by blocking macrophage-to-myofibroblast transition through TGF-/Smad3 signaling.

Non-RCTAnimal StudyRigorous JournalHighly Cited

2022·

80citations

·Junzhe Chen et al.

Molecular therapy : the journal of the American Society of Gene Therapy·

DOI

Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

Clopidogrel and ticlopidine show potent mechanism-based inhibition of human CYP2B6 and CYP2C19, suggesting potential drug interactions between these thienopyridine derivates and their drug substrates.

In Vitro StudyHighly Cited

2004·

271citations

·T. Richter et al.

Journal of Pharmacology and Experimental Therapeutics·

DOI

Pleiotropic effects of clopidogrel

Clopidogrel has both platelet-independent and platelet-independent effects in various tissues, with understudied metabolites potentially mediating these effects.

2022·

21citations

·Dawn S. Kuszynski et al.

Purinergic Signalling·

DOI

Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.

Clopidogrel effectively treats ischemic cerebrovascular, cardiac, and peripheral arterial diseases by impairing platelet P2Y(AC) ADP receptor-mediated signaling, including decreased VASP phosphorylation.

Non-RCTHighly Cited

1999·

248citations

·J. Geiger et al.

Arteriosclerosis, thrombosis, and vascular biology·

DOI

Vasomodulatory action of clopidogrel and ticlopidine.

Clopidogrel and ticlopidine both produce dose-dependent vasomodulatory actions in rabbit and rat tissues, potentially contributing to their clinical effects in arterial disorders.

Non-RCTAnimal Study

1997·

34citations

·L. Yang et al.

Thrombosis research·

DOI

P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.

P2Y(12) inhibitors cangrelor and ticagrelor differ in their properties and mechanisms of action compared to clopidogrel, potentially impacting their clinical use in patients with acute coronary syndrome and percutaneous coronary intervention.

Systematic ReviewHighly Cited

2009·

327citations

·L. Wallentin

European heart journal·

DOI

Try another search

surface temperature of Pluto

effectiveness of multivitamin supplements

listerine antimicrobial effects

metoprolol succinate clinical studies

foods that lower cholesterol

international space station visibility